NEW YORK ( TheStreet) -- CHANGE IN RATINGSAmylin Pharmaceuticals ( AMLN) downgraded at BMO from Market Perform to Underperform. $12 price target. LAR approval could be delayed until late 2011, as the FDA will likely request more clinical data. Avery Dennison ( AVY) downgraded at BofA/Merrill to Neutral from Buy as valuation and fundamentals are less compelling. $35 price target. Boeing ( BA) upgraded at UBS from Sell to Neutral. $68 price target. Estimates also boosted, because of a higher delivery forecast. Convergys ( CVG) downgraded at Kaufman from Hold to Sell. Valuation call, as the stock is up 16% since the recent CEO change. $11 price target. Disney ( DIS) upgraded at BofA/Merrill to Buy from Neutral on expectations that 2011 earnings will beat expectations. Estimates raised through 2012. Price target boosted to $42 from $33. Dole Food ( DOLE) rated new Equal-weight at Morgan Stanley. Core fruit business has limited upside potential from current levels. FedEx ( FDX) upgraded at Morgan Keegan from Market Perform to Outperform. Company has strong earnings leverage as volumes recover. Coca-Cola ( KO) upgraded at UBS from Neutral to Buy. $62 price target. Valuation call, as the company has been showing strong volume and cash flow growth. Liberty Starz ( LSTZA) rated new Buy at UBS. $65 price target. Stock is overly discounting future programming costs and sports and attractive 10% free cash flow yield. Madison Square Garden ( MSG) rated new Neutral at UBS. Coverage of MSG was started with a Neutral rating. $22 price target. Company will spend more to upgrade its arena in 2011. Valuation also appears high. Royal Caribbean ( RCL) upgraded at Goldman from Sell to Neutral. Estimates also raised, as the new Oasis and Solstice ships are showing a significant relative premium. $27 price target. Spirit Aerosystems ( SPR) upgraded at UBS from Sell to Neutral. $22 price target. Higher deliveries should drive earnings.